Hepatic fibrosis 2022: Unmet needs and a blueprint for the future

Scott L. Friedman, Massimo Pinzani – 18 December 2021 – Steady progress over four decades toward understanding the pathogenesis and clinical consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet none has been approved. Thus, an assessment of the field is timely, to clarify priorities and accelerate progress. Here, we highlight the successes to date but, more importantly, identify gaps and unmet needs, both experimentally and clinically.

Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Nicole E. Rich, Amit G. Singal – 18 December 2021 – Overdiagnosis refers to detection of disease that would not otherwise become clinically apparent during a patient’s lifetime. Overdiagnosis is common and has been reported for several cancer types, although there are few studies describing its prevalence in HCC surveillance programs. Overdiagnosis can have serious negative consequences including overtreatment and associated complications, financial toxicity, and psychological harms related to being labeled with a cancer diagnosis.

Survival Benefit of Split‐Liver Transplantation for Pediatric and Adult Candidates

Mary G. Bowring, Allan B. Massie, Kathleen B. Schwarz, Andrew M. Cameron, Elizabeth A. King, Dorry L. Segev, Douglas B. Mogul – 17 December 2021 – Patient and graft survival are similar following whole‐liver transplantations (WLTs) versus split‐liver transplantations (SLTs) among pediatric and adult recipients, yet SLTs are rarely used.

Subscribe to